Your session is about to expire
← Back to Search
Tranexamic Acid for Spinal Deformity
Study Summary
This trial is testing whether using tranexamic acid (TXA) both intravenously and topically can decrease blood loss and transfusion requirements in adult patients compared to using TXA intravenously alone during posterior spinal surgery for adult deformity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My surgery will be done using the anterior approach.I am between 18 and 80 years old.I am scheduled for a major spine surgery for scoliosis or joint disease, including fusion to the pelvis.I have had a clot-related event less than a year before my surgery.I have been diagnosed with a seizure disorder or have had a seizure before.I have had a dural tear that was not repaired, confirmed by MRI or surgery.I have donated my own blood before surgery.I have kidney or liver problems.I have leukemia or another active cancer.I cannot stop my blood thinner medication for surgery.I have atrial fibrillation.I have had heart issues (like a heart attack or needed a stent) within the last year.I am taking ASA 325 and cannot stop it 10 days before surgery.I have a condition that causes my blood to clot more than normal.
- Group 1: IV TXA + topical placebo
- Group 2: ivTXA + topical TXA
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA cleared Tranexamic Acid 100 MG/ML for public consumption?
"Tranexamic Acid 100 MG/ML has received a safety score of 3 due to the fact that this is a Phase 3 trial. This signifies that, not only is there some data supporting efficacy, but also multiple rounds of data affirming its safety."
How many people can join this research project?
"Yes, this study is still open and currently recruiting patients. The listing was created on July 11th, 2018 and updated as recently as August 11th, 2020. They are looking for 100 people to participate at 1 site."
Is the data on Tranexamic Acid 100 MG/ML conclusive?
"Currently, there are 68 active studies involving Tranexamic Acid 100 MG/ML. Of these, 29 are in Phase 3. The largest number of sites for these trials is based out of Kansas City, but there are a total of 304 locations running these tests."
Are geriatric patients applicable for this research?
"The aim of this clinical trial is to test the efficacy of the proposed intervention in patients that are at least 18 years old but no more than 80."
Who meets the qualifications to participate in this research?
"This trial has a 100 patient quota and is currently looking for individuals who have experienced blood loss, surgery, and are between 18-80 years old."
What indications does Tranexamic Acid 100 MG/ML commonly cover?
"Tranexamic Acid 100 MG/ML is a common medication used to treat hyperfibrinolysis, but it can also be given for other reasons like hemophilia, bleeding, or tooth extractions."
Are there any vacancies for this research project?
"Yes, this is an ongoing trial that was posted on 7/11/2018 and updated as recently as 8/11/2022. They are enrolling 100 individuals at 1 location."
Share this study with friends
Copy Link
Messenger